0610009B22Rik Inhibitors
The protein coded by the gene 0610009B22Rik plays a significant role in cellular processes, contributing to the intricate network of biological functions that sustain cellular homeostasis. Understanding how the expression of this protein can be inhibited is of substantial interest in the field of molecular biology and biochemistry. Various chemical compounds have been identified that can potentially downregulate the expression of 0610009B22Rik by targeting different stages of the gene expression pathway. For instance, some compounds interfere with the transcription process by inhibiting RNA polymerase II, which is pivotal in transcribing DNA into mRNA. Others obstruct protein synthesis by acting at the translational level, preventing the proper assembly of the translation machinery or inducing premature chain termination. Additionally, certain inhibitors may trigger cellular stress responses, such as the unfolded protein response, which can indirectly result in the reduced expression of a host of proteins, including 0610009B22Rik.
Expanding our understanding of the mechanisms by which these inhibitors act provides valuable insights into the regulation of gene expression. Compounds such as Actinomycin D and α-Amanitin directly bind to DNA or inhibit RNA polymerase, respectively, curtailing the transcription of target genes. Cycloheximide and puromycin disrupt the normal progression of translation, leading to a reduction in protein synthesis. On the post-translational level, proteasome inhibitors like MG132 can prevent the degradation of misfolded proteins, causing a backlog in the protein quality control system and influencing the expression levels of various proteins. Another dimension is added by compounds that alter the epigenetic landscape, such as Epigallocatechin gallate (EGCG), which can suppress DNA methyltransferase activity, potentially resulting in the downregulation of gene expression through changes in DNA methylation patterns. By exploring the actions of these chemical compounds, researchers can gain deeper insight into the molecular dynamics that govern gene and protein regulation within the cell.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Triptolide | 38748-32-2 | sc-200122 sc-200122A | 1 mg 5 mg | $90.00 $204.00 | 13 | |
Triptolide is known to inhibit RNA polymerase II, potentially leading to a decrease in the transcription of the 0610009B22Rik gene by directly preventing the assembly of necessary transcriptional machinery on its promoter. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Brefeldin A disrupts the structure and function of the Golgi apparatus, which could lead to a cessation of vesicle-mediated transport and potentially downregulate the expression of 0610009B22Rik by inducing cellular stress responses that target protein trafficking. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $172.00 $305.00 | 66 | |
Tunicamycin blocks N-linked glycosylation in the endoplasmic reticulum, which could result in ER stress and activation of the unfolded protein response, leading to a reduction in global protein levels including those of 0610009B22Rik through enhanced degradation or decreased synthesis. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $74.00 $243.00 $731.00 $2572.00 $21848.00 | 53 | |
Actinomycin D binds to DNA, inhibiting RNA polymerase movement and subsequently decreasing the transcription of many genes, including 0610009B22Rik, by obstructing the elongation phase of mRNA synthesis. | ||||||
α-Amanitin | 23109-05-9 | sc-202440 sc-202440A | 1 mg 5 mg | $269.00 $1050.00 | 26 | |
α-Amanitin selectively inhibits RNA polymerase II, which would reduce the transcription of 0610009B22Rik by directly blocking the enzyme responsible for mRNA synthesis of this gene. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $41.00 $84.00 $275.00 | 127 | |
Cycloheximide inhibits eukaryotic protein synthesis by interfering with the translocation step on the ribosome, which would decrease the levels of many proteins, including 0610009B22Rik, by prematurely terminating polypeptide elongation. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits the mTOR pathway, which is crucial for initiating cap-dependent protein translation, leading to a reduction in the synthesis of proteins, potentially including 0610009B22Rik, by stalling the translation initiation complex. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG132 is a proteasome inhibitor that could lead to an accumulation of polyubiquitinated proteins, triggering ER stress and potentially decreasing the stability and expression of proteins such as 0610009B22Rik through an overwhelmed degradation pathway. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $69.00 | 2 | |
Chloroquine disrupts endosomal and lysosomal acidification, potentially leading to decreased degradation of autophagic vesicles, which in turn could lead to a reduction in the expression of proteins that rely on autophagy for their turnover, including 0610009B22Rik. | ||||||
Puromycin dihydrochloride | 58-58-2 | sc-108071 sc-108071B sc-108071C sc-108071A | 25 mg 250 mg 1 g 50 mg | $42.00 $214.00 $832.00 $66.00 | 394 | |
Puromycin causes premature termination of mRNA translation by acting as an analog of aminoacyl-tRNAs, which could lead to a decrease in the levels of newly synthesized proteins, including 0610009B22Rik, by inducing the release of nascent polypeptide chains. | ||||||